Division of Cardiology, St. Lukes Roosevelt Hospital, New York, NY, USA.
J Nucl Cardiol. 2010 Dec;17(6):999-1008. doi: 10.1007/s12350-010-9300-9. Epub 2010 Nov 13.
A higher frequency of clinical events has been observed in patients undergoing pharmacological vs exercise myocardial perfusion single-photon emission computed tomography (SPECT). While this difference is attributed to greater age and co-morbidities, it is not known whether these tests also differ in prognostic ability among patients with similar clinical profiles.
We assessed all-cause mortality rates in 6,069 patients, followed for 10.2 ± 1.7 years after undergoing exercise or adenosine SPECT. We employed propensity analysis to match exercise and adenosine subgroups by age, gender, symptoms, and coronary risk factors. Within our propensity-matched cohorts, adenosine patients had an annualized mortality rate event rates that was more than twice that of exercise patients (3.9% vs 1.6%, P < .0001). Differences in mortality persisted among age groups, including those <55 years old. In the exercise cohort, mortality was inversely related to exercise duration, with comparable mortality noted for patients exercising <3 min and those undergoing adenosine testing.
Among patients with normal stress SPECT tests, those undergoing adenosine testing manifest a mortality rate that is substantially higher than that observed among adequately exercising patients, but comparable to that observed among very poorly exercising patients. This elevated risk underscores an important challenge for managing patients undergoing pharmacological stress testing.
与运动心肌灌注单光子发射计算机断层扫描(SPECT)相比,接受药物治疗的患者发生临床事件的频率更高。虽然这种差异归因于年龄较大和合并症较多,但尚不清楚这些测试在具有相似临床特征的患者中的预后能力是否也存在差异。
我们评估了 6069 例患者的全因死亡率,这些患者在接受运动或腺苷 SPECT 检查后随访了 10.2±1.7 年。我们采用倾向分析,根据年龄、性别、症状和冠状动脉危险因素对运动和腺苷亚组进行匹配。在我们的倾向匹配队列中,腺苷患者的年化死亡率是运动患者的两倍多(3.9%比 1.6%,P<.0001)。在包括 55 岁以下患者在内的不同年龄组中,死亡率差异仍然存在。在运动组中,死亡率与运动时间呈反比,运动时间<3 分钟的患者和接受腺苷检测的患者死亡率相当。
在正常应激 SPECT 检查的患者中,接受腺苷检查的患者的死亡率明显高于充分运动的患者,与运动极差的患者相当。这种高风险突显了管理接受药物应激测试患者的重要挑战。